Medical Doctor Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Brian McLean

Addiction Medicine Loma Linda, CA Medical Doctor

NPI 1316173354 CMS profile 514189

11234 Anderson St, House Staff Office Cp 21005, Loma Linda, CA 92354

Open in the dashboard

General payments

$385

13 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brian McLean of Loma Linda, CA is reported in the CMS Open Payments database as having received $385 across 13 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $205 2
2024 General $166 10
2023 General $14 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brian McLean
  • Addiction Medicine median
  • Middle half of Addiction Medicine
  • National median

In program year 2025, general payments to Brian McLean were reported at $205. Among 29 Addiction Medicine profiles paid that year, the median was $133 and the middle half received between $46 and $264.

Show as a table
Year Brian McLean Addiction Medicine median Middle half National median
2019 $0 $59 $32–$190 $163
2020 $0 $82 $18–$173 $114
2021 $0 $74 $20–$145 $132
2022 $0 $68 $28–$179 $149
2023 $14 $63 $30–$239 $160
2024 $166 $73 $38–$190 $164
2025 $205 $133 $46–$264 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. MML US, Inc. $184 1 payment
  2. SPR Therapeutics, Inc $72 6 payments
  3. Nalu Medical, Inc. $69 4 payments
  4. Avanos Medical $39 1 payment
  5. Averitas Pharma Inc. $21 1 payment

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $385 13 payments
Products named General payments · program years 2023–2025
  1. ReActiv8 $184 1 payment
  2. SPRINT PNS System $72 6 payments
  3. Nalu Neurostimulation System $69 4 payments
  4. COOLIEF* COOLED RADIOFREQUENCY $39 1 payment
  5. Qutenza $21 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

79

Median for Addiction Medicine: 227

Drug cost

$2,436

Median for Addiction Medicine: $23,125

Branded share of claims

0%

Median for Addiction Medicine: 56%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Naltrexone Hcl Generic 47 $2,157
Gabapentin Generic 32 $278

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 382 Part D prescribers listed as Addiction Medicine; they describe a distribution and say nothing about conduct.

Records

13 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Addiction Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record